Speaker
Prof. Dr. André Scheen
Presentation title
Clinical inertia, a major concern in drug therapy
Presentation outline
Inertia in drug therapy is one of the components of clinical inertia and is now recognized as a major concern, besides patient’s poor compliance. It mainly concerns the management of chronic diseases. It may be defined as the attitude of health care providers who do not initiate or intensify therapy appropriately despite recognition of the problem. Multiple causes may be identified, related to the physician but also to the patient and to the health care system. The consequences may be dramatic, both for the patient, in terms of quality of life and/or life expectancy, and for the society, because of the huge cost resulting from complications due to therapeutic inertia. Thus, various solutions should be proposed to help solving this important public health problem, focusing the actions on the physician, the patient and/or the health care system. Examples will be discussed in the field of the management of diabetes, hypertension and dyslipidemias.
Job title
Professor Doctor André Scheen, Head of the Division of Diabetes, Nutrition & Metabolic Disorders and of the Clinical Pharmacology Unit, CHU Liège
Biography
André J. SCHEEN is Head of the Division of Diabetes, Nutrition and Metabolic Disorders and of the Clinical Pharmacology Unit, in the Department of Medicine of the Academic Hospital of Liège, CHU Sart Tilman, Liège, Belgium. He is also Full Professor of Medicine (Diabetes, Nutrition and Metabolic Disorders) and of Clinical Pharmacology and Therapeutics at the Faculty of Medicine of University of Liège, Belgium. He holds membership of many professional societies, including the European Association for the Study of Diabetes, the American Association of Diabetes and the European Association for the Study of Obesity. He is member of the board of the “Association Belge du Diabète”, an effective member of the “Commission Belge de Remboursement des Médicaments” and a full member of the "Académie Royale Belge de Médecine". He served also as President of the Belgian Lipid Club and of the Belgian Association for the Study of Obesity. Since December 2011, he is vice-president of the "Société Francophone du Diabète”. A. Scheen is Associate Editor of Diabetes & Metabolism, current Editor in Chief of the "Revue Médicale de Liège" and member of the Editorial Board of several national (Acta Clinica Belgica) and international scientific journals, including Expert Opinion on Drug Metabolism and Toxicology. He got several national and international prizes for his research work in the field of diabetes. He has contributed to more than 250 original papers in peer-review journals, 300 review articles and 75 book chapters. He served also as a referee for numerous medical journals in the field of Diabetes, Metabolic Disorders, Internal Medicine and Clinical Pharmacology.
List of publications
Scheen AJ. Rev Med Liège 2010, 65, 232-238
Scheen AJ, Giet D. Cibler l'inertie et le défaut d'observance thérapeutiques : nouveau défi pour améliorer les performances de la pratique médicale. Rev Med Liège, 2010, 65, 229-231.
Scheen AJ. Inertie thérapeutique dans la pratique médicale: causes, conséquences, solutions. Rev Med Liège, 2010, 65, 232-238.
Jandrain BJ, Ernest P, Radermecker RP, Scheen AJ. Stratégies pour éviter l'inertie et la non-observance dans les essais cliniques. Rev Med Liège, 2010, 65, 246-249.
Philips JC, Scheen AJ. Inertie clinique dans la prise en charge du patient diabétique de type 2 : quelles solutions proposer ? Rev Med Liège, 2010, 65, 318-325.
